Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

NCT01625234 is registered in ClinicalTrials.gov with Xcovery Holdings, Inc. as lead sponsor.

NCT NCT01625234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Lead sponsor
Xcovery Holdings, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2012
Completion date
September 17, 2020
Enrollment
131 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, non-small cell lung cancer